137 related articles for article (PubMed ID: 31307108)
21. Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas.
Evenepoel L; van Nederveen FH; Oudijk L; Papathomas TG; Restuccia DF; Belt EJT; de Herder WW; Feelders RA; Franssen GJH; Hamoir M; Maiter D; Ghayee HK; Shay JW; Perren A; Timmers HJLM; van Eeden S; Vroonen L; Aydin S; Robledo M; Vikkula M; de Krijger RR; Dinjens WNM; Persu A; Korpershoek E
J Clin Endocrinol Metab; 2018 Jan; 103(1):46-55. PubMed ID: 28938490
[TBL] [Abstract][Full Text] [Related]
22. 15 YEARS OF PARAGANGLIOMA: Genetics and mechanism of pheochromocytoma-paraganglioma syndromes characterized by germline SDHB and SDHD mutations.
Baysal BE; Maher ER
Endocr Relat Cancer; 2015 Aug; 22(4):T71-82. PubMed ID: 26113606
[TBL] [Abstract][Full Text] [Related]
23. Pheochromocytomas and extra-adrenal paragangliomas detected by screening in patients with SDHD-associated head-and-neck paragangliomas.
Havekes B; van der Klaauw AA; Weiss MM; Jansen JC; van der Mey AG; Vriends AH; Bonsing BA; Romijn JA; Corssmit EP
Endocr Relat Cancer; 2009 Jun; 16(2):527-36. PubMed ID: 19289533
[TBL] [Abstract][Full Text] [Related]
24. Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas.
; Toledo RA; Burnichon N; Cascon A; Benn DE; Bayley JP; Welander J; Tops CM; Firth H; Dwight T; Ercolino T; Mannelli M; Opocher G; Clifton-Bligh R; Gimm O; Maher ER; Robledo M; Gimenez-Roqueplo AP; Dahia PL
Nat Rev Endocrinol; 2017 Apr; 13(4):233-247. PubMed ID: 27857127
[TBL] [Abstract][Full Text] [Related]
25. Magnetic resonance spectroscopy of paragangliomas: new insights into in vivo metabolomics.
Varoquaux A; le Fur Y; Imperiale A; Reyre A; Montava M; Fakhry N; Namer IJ; Moulin G; Pacak K; Guye M; Taïeb D
Endocr Relat Cancer; 2015 Aug; 22(4):M1-8. PubMed ID: 26115958
[TBL] [Abstract][Full Text] [Related]
26. Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal.
Erlic Z; Kurlbaum M; Deutschbein T; Nölting S; Prejbisz A; Timmers H; Richter S; Prehn C; Weismann D; Adamski J; Januszewicz A; Reincke M; Fassnacht M; Robledo M; Eisenhofer G; Beuschlein F; Kroiss M
Eur J Endocrinol; 2019 Dec; 181(6):647-657. PubMed ID: 31614337
[TBL] [Abstract][Full Text] [Related]
27. New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.
Taïeb D; Pacak K
Trends Endocrinol Metab; 2017 Nov; 28(11):807-817. PubMed ID: 28867159
[TBL] [Abstract][Full Text] [Related]
28. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
[TBL] [Abstract][Full Text] [Related]
29. SDHD immunohistochemistry: a new tool to validate SDHx mutations in pheochromocytoma/paraganglioma.
Menara M; Oudijk L; Badoual C; Bertherat J; Lepoutre-Lussey C; Amar L; Iturrioz X; Sibony M; Zinzindohoué F; de Krijger R; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2015 Feb; 100(2):E287-91. PubMed ID: 25405498
[TBL] [Abstract][Full Text] [Related]
30. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.
Fishbein L; Khare S; Wubbenhorst B; DeSloover D; D'Andrea K; Merrill S; Cho NW; Greenberg RA; Else T; Montone K; LiVolsi V; Fraker D; Daber R; Cohen DL; Nathanson KL
Nat Commun; 2015 Jan; 6():6140. PubMed ID: 25608029
[TBL] [Abstract][Full Text] [Related]
31. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Toledo RA
Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
[TBL] [Abstract][Full Text] [Related]
32. Primary Renal Paragangliomas and Renal Neoplasia Associated with Pheochromocytoma/Paraganglioma: Analysis of von Hippel-Lindau (VHL), Succinate Dehydrogenase (SDHX) and Transmembrane Protein 127 (TMEM127).
Gupta S; Zhang J; Milosevic D; Mills JR; Grebe SK; Smith SC; Erickson LA
Endocr Pathol; 2017 Sep; 28(3):253-268. PubMed ID: 28646318
[TBL] [Abstract][Full Text] [Related]
33. Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours.
Tsang VH; Dwight T; Benn DE; Meyer-Rochow GY; Gill AJ; Sywak M; Sidhu S; Veivers D; Sue CM; Robinson BG; Clifton-Bligh RJ; Parker NR
Endocr Relat Cancer; 2014 Jun; 21(3):415-26. PubMed ID: 24623741
[TBL] [Abstract][Full Text] [Related]
34. Utility of the succinate: Fumarate ratio for assessing SDH dysfunction in different tumor types.
Kim E; Wright MJ; Sioson L; Novos T; Gill AJ; Benn DE; White C; Dwight T; Clifton-Bligh RJ
Mol Genet Metab Rep; 2017 Mar; 10():45-49. PubMed ID: 28070496
[TBL] [Abstract][Full Text] [Related]
35. Imaging work-up for screening of paraganglioma and pheochromocytoma in SDHx mutation carriers: a multicenter prospective study from the PGL.EVA Investigators.
Gimenez-Roqueplo AP; Caumont-Prim A; Houzard C; Hignette C; Hernigou A; Halimi P; Niccoli P; Leboulleux S; Amar L; Borson-Chazot F; Cardot-Bauters C; Delemer B; Chabolle F; Coupier I; Libé R; Peitzsch M; Peyrard S; Tenenbaum F; Plouin PF; Chatellier G; Rohmer V
J Clin Endocrinol Metab; 2013 Jan; 98(1):E162-73. PubMed ID: 23162105
[TBL] [Abstract][Full Text] [Related]
36. Updates on the genetics and the clinical impacts on phaeochromocytoma and paraganglioma in the new era.
Pillai S; Gopalan V; Smith RA; Lam AK
Crit Rev Oncol Hematol; 2016 Apr; 100():190-208. PubMed ID: 26839173
[TBL] [Abstract][Full Text] [Related]
37. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.
Currás-Freixes M; Inglada-Pérez L; Mancikova V; Montero-Conde C; Letón R; Comino-Méndez I; Apellániz-Ruiz M; Sánchez-Barroso L; Aguirre Sánchez-Covisa M; Alcázar V; Aller J; Álvarez-Escolá C; Andía-Melero VM; Azriel-Mira S; Calatayud-Gutiérrez M; Díaz JÁ; Díez-Hernández A; Lamas-Oliveira C; Marazuela M; Matias-Guiu X; Meoro-Avilés A; Patiño-García A; Pedrinaci S; Riesco-Eizaguirre G; Sábado-Álvarez C; Sáez-Villaverde R; Sainz de Los Terreros A; Sanz Guadarrama Ó; Sastre-Marcos J; Scolá-Yurrita B; Segura-Huerta Á; Serrano-Corredor Mde L; Villar-Vicente MR; Rodríguez-Antona C; Korpershoek E; Cascón A; Robledo M
J Med Genet; 2015 Oct; 52(10):647-56. PubMed ID: 26269449
[TBL] [Abstract][Full Text] [Related]
38. Whole-exome sequencing identifies MDH2 as a new familial paraganglioma gene.
Cascón A; Comino-Méndez I; Currás-Freixes M; de Cubas AA; Contreras L; Richter S; Peitzsch M; Mancikova V; Inglada-Pérez L; Pérez-Barrios A; Calatayud M; Azriel S; Villar-Vicente R; Aller J; Setién F; Moran S; Garcia JF; Río-Machín A; Letón R; Gómez-Graña Á; Apellániz-Ruiz M; Roncador G; Esteller M; Rodríguez-Antona C; Satrústegui J; Eisenhofer G; Urioste M; Robledo M
J Natl Cancer Inst; 2015 Mar; 107(5):. PubMed ID: 25766404
[TBL] [Abstract][Full Text] [Related]
39. Succinate-Dehydrogenase Deficient Paragangliomas/Pheochromocytomas: Genetics, Clinical Aspects and Mini- Review.
Rusyn L; Kohn B
Pediatr Endocrinol Rev; 2017 Mar; 14(3):312-325. PubMed ID: 28508602
[No Abstract] [Full Text] [Related]
40. Epigenetic Mutation of the Succinate Dehydrogenase C Promoter in a Patient With Two Paragangliomas.
Richter S; Klink B; Nacke B; de Cubas AA; Mangelis A; Rapizzi E; Meinhardt M; Skondra C; Mannelli M; Robledo M; Menschikowski M; Eisenhofer G
J Clin Endocrinol Metab; 2016 Feb; 101(2):359-63. PubMed ID: 26652933
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
